Quantisnow Logo
Dashboard

Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

$XRAY
Medical/Dental Instruments
Health Care
Get the next $XRAY alert in real time by email
SC 13G/A 1 UnitedStates_13G__DENTSPLYSI.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 17)* (Name of Issuer) DENTSPLY SIRONA Inc (Title of Class of Securities) Common Stock (CUSIP Number) 24906P109 (Date of Event Which Requires Filing of this Statement) November 29, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 24906P109 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 149,574 (7) Sole dispositive power 19,884,312 (8) Shared dispositive power 395,273 (9) Aggregate amount beneficially owned by each reporting person 20,279,585 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 10.20% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: DENTSPLY SIRONA Inc Item 1(b) Address of issuer's principal executive offices: 13320 Ballantyne Corporate Pl Charlotte, NC 28277 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 24906P109 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on November 29, 2024: (a) Aggregate amount beneficially owned: 20,279,585 (b) Percent of class: 10.20% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 20,279,585 (b) Percent of class: 10.20% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 149,574 (iii) Sole power to dispose or to direct the disposition of: 19,884,312 (iv) Shared power to dispose or to direct the disposition of: 395,273 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: December 06, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration
Get the next $XRAY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XRAY

DatePrice TargetRatingAnalyst
3/13/2025Buy → Hold
Needham
2/14/2025$20.00Equal Weight
Wells Fargo
1/23/2025$30.00 → $20.00Buy → Hold
Jefferies
1/7/2025$20.00Outperform → In-line
Evercore ISI
12/4/2024$21.00Neutral
Mizuho
11/7/2024Outperform → Market Perform
Leerink Partners
10/25/2024$34.00 → $29.00Buy
Needham
8/20/2024$34.00Buy
Needham
More analyst ratings

$XRAY
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader

    CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se

    $XRAY
    Medical/Dental Instruments
    Health Care

  • Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2025

    CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare Conference. Management is scheduled to present on Tuesday, March 11, 2025, at 3:00 pm ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and

    $XRAY
    Medical/Dental Instruments
    Health Care

  • Dentsply Sirona Reports Fourth Quarter and Full Year 2024 Results, Provides Full Year 2025 Outlook

    FY24 net sales of $3,793 million decreased (4.3%), organic sales decreased (3.5%) including a (1.2%) Byte sales impactFY24 GAAP net loss of ($910) million or ($4.48) per share, adjusted EPS of $1.67Q4 net sales of $905 million decreased (10.6%), organic sales decreased (10.7%) including a (6.0%) Byte sales impactQ4 GAAP net loss of ($430) million or ($2.16) per share, adjusted EPS of $0.26FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00(1) CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial resul

    $XRAY
    Medical/Dental Instruments
    Health Care

$XRAY
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$XRAY
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$XRAY
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$XRAY
 SEC Filings

See more

$XRAY
 Leadership Updates

Live Leadership Updates

See more

  • Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader

    CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se

    $XRAY
    Medical/Dental Instruments
    Health Care

  • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

    $EXAS
    $GE
    $GMED
    $XRAY
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology

  • Dentsply Sirona Appoints Herman V. Cueto Interim Chief Financial Officer

    CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Herman V. Cueto, a seasoned healthcare executive, has been appointed Interim Chief Financial Officer, effective immediately. He brings over two decades of experience leading and working in finance organizations across the healthcare industry. Mr. Cueto will oversee the finance organization while Dentsply Sirona completes its ongoing search for the Company's next CFO. "We are fortunate to have Herman joining us as interim CFO during this important time in Dentsply Sirona's history," said Simon Campion, President and Chief Executive Officer. "Herman

    $XRAY
    Medical/Dental Instruments
    Health Care

$XRAY
 Financials

Live finance-specific insights

See more

  • Dentsply Sirona Reports Fourth Quarter and Full Year 2024 Results, Provides Full Year 2025 Outlook

    FY24 net sales of $3,793 million decreased (4.3%), organic sales decreased (3.5%) including a (1.2%) Byte sales impactFY24 GAAP net loss of ($910) million or ($4.48) per share, adjusted EPS of $1.67Q4 net sales of $905 million decreased (10.6%), organic sales decreased (10.7%) including a (6.0%) Byte sales impactQ4 GAAP net loss of ($430) million or ($2.16) per share, adjusted EPS of $0.26FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00(1) CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial resul

    $XRAY
    Medical/Dental Instruments
    Health Care

  • Dentsply Sirona Initiates Review of Strategic Alternatives for Wellspect Healthcare

    CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business ("Wellspect"). Wellspect is a leading provider of bladder and bowel management care products with an over 40-year history. Through its comprehensive portfolio of products and accessories from trusted brands like LoFric® and Navina™, Wellspect has delivered improved organic sales growth in recent years, including mid-to-high single digit growth for 2023 and through the first three quarters of 2024. The business is well-positioned in the larg

    $XRAY
    Medical/Dental Instruments
    Health Care

  • Dentsply Sirona to Host Fourth Quarter and Full Year 2024 Conference Call on February 27th

    CHARLOTTE, N.C., Jan. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, February 27, 2025, at 8:30 am ET to review its fourth quarter and full year 2024 financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register

    $XRAY
    Medical/Dental Instruments
    Health Care

$XRAY
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more